Expertise in
1
conditions

Eric D. Adler

Holistic Medicine
334 Roosevelt Ave, 
Freeport, NY 
Expertise in
1
conditions
334 Roosevelt Ave, 
Freeport, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Adler is a Holistic Medicine provider in Freeport, New York. Mr. Adler is highly rated in 1 condition, according to our data. His top areas of expertise are Phosphoglycerate Mutase Deficiency, Paroxysmal Supraventricular Tachycardia (PSVT), Heart Failure with Preserved Ejection Fraction (HFpEF), and Transthyretin Amyloid Cardiomyopathy.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Holistic Medicine
Licenses
Acupuncturist in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

334 Roosevelt Ave, Freeport, NY 11520

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)
Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 2
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
Enrollment Status: Completed
Publish Date: March 27, 2025
Intervention Type: Drug, Device
Study Phase: Not Applicable
THEME Registry: TandemHeart Experiences and MEthods (THEME Registry)
THEME Registry: TandemHeart Experiences and MEthods (THEME Registry)
Enrollment Status: Terminated
Publish Date: September 21, 2023
Intervention Type: Device
Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation in Patients With Pulmonary Hypertension Due to Left Heart Disease
Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation in Patients With Pulmonary Hypertension Due to Left Heart Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2023
Intervention Type: Device
Study Phase: Not Applicable
Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up
Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ Continued Access Protocol: Post-Approval Continued Follow-up
Enrollment Status: Completed
Publish Date: June 27, 2022
Intervention Type: Device
Study Phase: Not Applicable
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor to HCVNegative Organ Transplant Recipient - Pilot Trial
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor to HCVNegative Organ Transplant Recipient - Pilot Trial
Enrollment Status: Completed
Publish Date: May 24, 2022
Intervention Type: Drug
Study Drug: Glecaprevir/Pibrentasvir
Study Phase: Phase 1/Phase 2
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Biological, Other
Study Phase: Phase 3
Rate Response With CLS Versus Accelerometer and Effect on Both Subjective Symptoms and Objective Outcomes in a Heart Failure Population Implanted With Cardiac Resynchronization With Defibrillator Device: The CLASS Trial
Rate Response With CLS Versus Accelerometer and Effect on Both Subjective Symptoms and Objective Outcomes in a Heart Failure Population Implanted With Cardiac Resynchronization With Defibrillator Device: The CLASS Trial
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Device
Study Phase: Not Applicable
Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: A Multicenter Study
Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: A Multicenter Study
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 9 Less Clinical Trials

166 Total Publications

Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy.
Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy.
Journal: JHLT open
Published: November 28, 2025
Similar Doctors
Min Zhang
Expertise in
23
conditions
Dr. Min Zhang
Holistic Medicine
Expertise in
23
conditions
Dr. Min Zhang
Holistic Medicine

Office

247 W 35th St Fl 10, 
New York, NY 
 (22.8 miles away)
212-244-3919
Languages Spoken:
English

Min Zhang is a Holistic Medicine provider in New York, New York. Mr. Zhang is highly rated in 23 conditions, according to our data. His top areas of expertise are Balantidiasis, Liver Failure, Gallbladder Disease, Bone Marrow Aspiration, and Endoscopy.

Lei Jin
Expertise in
1
conditions
Lei Jin
Holistic Medicine
Expertise in
1
conditions
Lei Jin
Holistic Medicine

DCJ Acupuncture PC

14241 41st Ave Unit 9, 
Flushing, NY 
 (14.4 miles away)
646-755-9255
Languages Spoken:
English
See accepted insurances

Lei Jin is a Holistic Medicine provider in Flushing, New York. Mr. Jin is highly rated in 1 condition, according to our data. His top area of expertise is Anencephaly.

Expertise in
15
conditions
Ying X. Chen
Holistic Medicine
Expertise in
15
conditions
Ying X. Chen
Holistic Medicine
2626 141st St Apt 3g, 
Flushing, NY 
 (15.4 miles away)
917-952-0999
Languages Spoken:
English

Ying Chen is a Holistic Medicine provider in Flushing, New York. Ms. Chen is highly rated in 15 conditions, according to our data. Her top areas of expertise are Microtia, Lowe Syndrome, Pulmonary Fibrosis, Endoscopy, and Osteotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Adler's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile